LOS ANGELES--(BUSINESS WIRE)--
MedMen Enterprises Inc. (MMEN.CN) (MMNFF) (FSE:A2JM6N) (“MedMen†or the “Companyâ€), is pleased to announce that it has signed a binding term sheet for a senior secured convertible credit facility of up to US$250,000,000 (the “Facilityâ€) from funds managed by Gotham Green Partners (“GGP†or the “Investorâ€), an investor in the global cannabis industry. Management believes this is the largest investment to date by a single investor in a publicly traded cannabis company with U.S. operations.
“This strategic partnership with Gotham Green Partners represents another key milestone for MedMen and stems from our long-standing relationship with The Cronos Group and GGP’s brand portfolio,†said Adam Bierman, CEO of MedMen. “The growth capital will be used to operationalize the balance of our footprint and we look forward to creating further alignment with GGP and their global cannabis platform.â€
“We continue to be impressed with MedMen’s industry leading retail execution and iconic branding. With MedMen’s fortified balance sheet, the Company’s future has never been brighter,†said Jason Adler, managing member of GGP. “We feel fortunate to have the opportunity to take such a significant stake in MedMen and begin to work actively with the management team and the board to help the Company achieve its goals.â€
The Company intends to use the net proceeds from drawdowns on the Facility to fund the future capital needs of the business. In addition to funding general working capital, the growth capital will primarily be used to:
The investment from GGP will be in the form of convertible senior secured notes issued by MM CAN USA, Inc., a subsidiary of the Company, totaling up to US$250,000,000 (“Notesâ€) on a private placement basis pursuant to applicable securities laws exemptions. The Notes will be issuable in three tranches, with each of the second and third tranches being issuable at the option of the Company, subject to certain conditions and share price thresholds being achieved by MedMen. The initial tranche will be in the amount of US$100,000,000 (“Tranche Iâ€). The additional US$150,000,000 would be funded in two US$75,000,000 tranches. The second tranche (“Tranche IIâ€) would be available to the Company beginning on the six-month anniversary of the closing date, and the third tranche (“Tranche IIIâ€) would be available to the Company beginning on the six-month anniversary of the funding date of Tranche II.
All Notes will have a maturity date of 36 months from the closing date (“Maturity Dateâ€), with a 12-month extension feature available to the Company on certain conditions, including payment of an extension fee. Notes will bear interest from their date of issue at LIBOR + 6.0% per annum. During the first 12 months, interest may be paid-in-kind (“PIKâ€) at the Company’s option such that any amount of PIK interest will be added to the outstanding principal of the Notes. The Company shall have the right after the first year, to prepay the outstanding principal amount of the Notes prior to maturity, in whole or in part, upon payment of 105% of the principal amount in the second year and 103% of the principal amount thereafter.
All or a portion of the Notes (including all accrued interest thereon) will be convertible, at the option of the holder, into class B subordinate voting shares of the Company (the “Subordinate Voting Sharesâ€) at any time prior to the close of business on the last business day immediately preceding the Maturity Date. The conversion price of each tranche of Notes is as follows:
i) for Tranche I Notes, the conversion price will be equal to 115% of the lesser of (the “Tranche I Reference Priceâ€) (a) US$3.10, which represents the closing price of the Subordinate Voting Shares on the Canadian Securities Exchange (the “CSEâ€) on the trading day immediately preceding the announcement of the Facility (translated to US dollars), and (b) the closing price of the Subordinate Voting Shares on the trading day immediately preceding the closing date; and
ii) for Tranche II and Tranche III Notes, the conversion price will be equal to the lesser of (a) 115% of the 20 trading day volume weighted average trading price of the Subordinate Voting Shares as of the trading day immediately preceding the date of issue of such tranche, and (b) US$7.00.
The Company may force the conversion of up to 75% of the then outstanding Notes at the applicable conversion price(s) if the volume weighted average trading price of the Subordinate Voting Shares (translated to US dollars) is US$8.00 for any 20 consecutive trading day period. If 75% of the then outstanding Notes are converted by the Company, the term of the remaining 25% of the then outstanding Notes will be extended by 12 months.
Upon drawdown of Tranche I, the lenders would be issued share purchase warrants (“Warrantsâ€), each of which would be exercisable to purchase one Subordinate Voting Share. The number of Warrants to be issued will represent an approximate 50% Warrant coverage on the Tranche 1 Notes, certain of which Warrants will have an exercise price per Subordinate Voting Share that will be equal to a 30% premium to the Tranche I Reference Price, and another group of which Warrants will have an exercise price per Subordinate Voting Share that will be equal to a 50% premium to the Tranche I Reference Price. The Warrant coverage on the Tranche II and Tranche III Notes will be similar to those for the Tranche I Notes. The exercise prices for the Warrants on the Tranche II and Tranche III Notes will be equal to the lesser of (a) a 30% or 50% (as the case may be) premium to the 20 trading day volume weighted average trading price of the Subordinate Voting Shares as of the trading day immediately preceding the date of the drawdowns of such tranches, and (b) US$7.91 or US$9.13 (as the case may be).
The Warrants and any Subordinate Voting Shares issuable upon conversion of the Notes or exercise of the Warrants, will be subject to a four month hold period from the date of issuance of the Notes or such Warrants, as applicable, in accordance with applicable Canadian securities laws.
The terms of the Facility described in this press release are those set out in a binding term sheet. However, completion of any tranche is subject to further agreements being entered into by the parties, including as to the guarantees and/or the collateral to be provided by MedMen and its applicable subsidiaries to secure its obligations under the Facility. The terms of the Facility, the Notes and the Warrants and the conditions to drawdowns are subject to change as the parties negotiate such definitive documentation. The closing of any tranches will be subject to certain conditions being satisfied including, but not limited to, the receipt of all necessary approvals and the absence of material adverse changes. The parties are currently anticipating a closing in April. There can be no assurance that the parties will enter into definitive documentation such that the Facility will be available, or if definitive documentation is entered into, that the terms of the Facility, the Notes and the Warrants and the conditions to receiving the proceeds of any of the tranches will be as stated above.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.
ABOUT MEDMEN:
MedMen is a cannabis retailer with operations across the U.S. and
flagship stores in Los Angeles, Las Vegas and New York. MedMen’s
mission is to provide an unparalleled experience that invites the
world to discover the remarkable benefits of cannabis because a
world where cannabis is legal and regulated is a safer, healthier
and happier world. Learn more at www.medmen.com
ABOUT GOTHAM GREEN PARTNERS:
Gotham Green Partners, LLC is a New York and California-based
private equity firm focused on deploying capital into cannabis and
cannabis-related enterprises on a global scale. The firm manages a
diversified portfolio of investments and is actively investing
across the cannabis value chain.
SOURCE: MedMen Enterprises
Cautionary Note Regarding Forward-Looking Information and Statements:
This press release contains certain “forward-looking information†within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements†within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only MedMen’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of MedMen’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plansâ€, “expects†or “does not expectâ€, “is expectedâ€, “budgetâ€, “scheduledâ€, “estimatesâ€, “forecastsâ€, “intendsâ€, “anticipates†or “does not anticipateâ€, or “believesâ€, or variations of such words and phrases or may contain statements that certain actions, events or results “mayâ€, “couldâ€, “wouldâ€, “might†or “will be takenâ€, “will continueâ€, “will occur†or “will be achievedâ€. The forward-looking information and forward-looking statements contained herein may include, but is not limited to, expectations that definitive documentation for the Facility will be entered into, information concerning the terms of the proposed Facility, Notes and Warrants, timing for completion of Tranche 1 of the Facility, the use of proceeds of the Facility and the impact of such use of proceeds of the Facility on the business, assets, liabilities, financial condition, performance and prospects of MedMen.
By identifying such information and statements in this manner, MedMen is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedMen to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, MedMen has made certain assumptions. Although MedMen believes that the assumptions used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. Key assumptions used herein are that the parties will negotiate mutually acceptable definitive documentation, that the Facility will be entered into, that the current terms and anticipated timing will not change and that MedMen will be able to satisfy the conditions to drawdown on Tranche II and Tranche III of the Facility. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and MedMen does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to MedMen or persons acting on its behalf is expressly qualified in its entirety by this notice.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190322005114/en/